CMS HAS YET TO PUZZLE OUT HOW TO LOWER MEDICARE PREMIUMS EVEN AFTER BIOGEN CUT ADUHELM’S PRICE AND MEDICARE OPTED NOT TO COVER THE PRODUCT OUTSIDE OF TRIALS. • Source: Getty
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
